Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Aiming to Enter Top 10 Next Year: Mr Dunoyer of GSK
December 31, 2001
- Fujisawa Licenses Tacrolimus-coated Stents to JOMED of Netherlands
December 31, 2001
- New Year's Greeting
December 31, 2001
- Appropriate Use of Insulin Explained: Novo Nordisk Seminar
December 31, 2001
- What Price Do Patients Pay?
December 31, 2001
- Chuikyo Approves Inclusion of Zithromac in NHI Price List
December 31, 2001
- Medical Fees to Decrease 1.3%
December 31, 2001
- POCT Market to Expand from 2003
December 31, 2001
- Price Discrepancy Rates Vary 5.7% to 9.6% According to Therapeutic Category
December 31, 2001
- WORLD NEWA IN BRIEF
December 31, 2001
- Chuikyo Recommends Price Cut for Long-listed Products
December 31, 2001
- Original Drugs with Generics Only to Be Subject to Additional Price Cut
December 31, 2001
- REGULATORY NEWS IN BRIEF
December 31, 2001
- Kissei, Novartis Make Alliance for Agent for Glaucoma
December 31, 2001
- Sankyo to Copromote CS-866 with Forest Laboratories in US
December 31, 2001
- S-P to Increase Its MRs to 600 to Detail Ribavirin
December 31, 2001
- Tanabe's Remicade Approved for Crohn: CDFS
December 24, 2001
- Oxford GlycoSciences Hoping to Form Japanese Alliances
December 24, 2001
- Panel Recommends On-line Medical Billing
December 24, 2001
- REGULATORY NEWS IN BRIEF
December 24, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…